Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Daolin Ji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9029-3801; OpenAlex author ID A5054438222. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. The functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via mi… Co-author DOI 10.3389/fphar.2025.1613560↗
  2. Deoxyelephantopin Suppresses Pancreatic Cancer Progression In Vitro and In Vivo by Targeting linc00511/miR-370-5p/p21 Promoter Axis. Co-author DOI 10.1155/2022/3855462↗
  3. Transcriptional ITPR3 as potential targets and biomarkers for human pancreatic cancer. Co-author DOI 10.18632/aging.204080↗
  4. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-κB signaling pathwa… Co-author DOI 10.18632/aging.103327↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Xu · 4 shared papers, 2020–2025 · strength 0.64
  2. Gang Tan · 2 shared papers, 2022–2025 · strength 0.39
  3. Yunfu Cui · 2 shared papers, 2020–2022 · strength 0.25
  4. Wangyang Zheng · 2 shared papers, 2020–2022 · strength 0.25
  5. Pengcheng Kang · 1 shared paper, 2020 · strength 0.11
  6. Xiangyu Zhong · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.